---
title: "Brentuximab Vedotin - Hodgkin'S Disease"
sidebar: mydoc_sidebar
permalink: db08870-mesh-d006689-1.html
toc: false 
---


Path ID: `DB08870_MESH_D006689_1`
{% include image.html url="images/db08870-mesh-d006689-1.png" file="db08870-mesh-d006689-1.png" alt="db08870-mesh-d006689-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:C547738 | brentuximab vedotin | Drug |
| UniProt:P28908 | Tumor necrosis factor receptor superfamily member 8 | Protein |
| CL:0001063 | tumor cell | Cell |
| MESH:C495575 | monomethyl auristatin E | ChemicalSubstance |
| GO:0008219 | Cell death | BiologicalProcess |
| MESH:D006689 | Hodgkin's disease | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Brentuximab Vedotin | MOLECULARLY INTERACTS WITH | Tumor Necrosis Factor Receptor Superfamily Member 8 |
| Tumor Necrosis Factor Receptor Superfamily Member 8 | EXPRESSED IN | Tumor Cell |
| Brentuximab Vedotin | COEXISTS WITH | Monomethyl Auristatin E |
| Monomethyl Auristatin E | CAUSES | Cell Death |
| Tumor Cell | ENABLES | Cell Death |
| Cell Death | NEGATIVELY CORRELATED WITH | Hodgkin'S Disease |
|---------|-----------|---------|

Comment: Brentuximab vedotin is anantibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE)

Reference: 
  - [https://go.drugbank.com/drugs/DB08870](https://go.drugbank.com/drugs/DB08870)
